报价延迟最少15分钟:2025/07/20 16:46 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.25 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.22/-1.19
|
|
企业价值
354.47M
|
| 资产负债 |
|
每股账面净值
1.76
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
22.00K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 16:46 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts. |
